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INTRODUCTION
                                                   INTRODUCTION
1. DIABETUS MELLITUS
The  term  diabetes  mellitus  describes  a  metabolic  disorder  of  multiple  aetiology
characterized  by  chronic  hyperglycemia  with  disturbances  of  carbohydrate,  fat  and  protein
metabolism resulting from defects in insulin secretion, insulin action,  or both. The effects of
diabetes mellitus include long-term damage, dysfunction and failure of various organs.1
Diabetes  mellitus  may present  with  characteristic  symptoms  such  as  thirst,  polyuria,
blurring of  vision,  and  weight  loss.  In  its  most  severe  forms,  ketoacidosis  or  a  non-ketotic
hyperosmolar state may develop and lead to stupor, coma and, in absence of effective treatment
cause death. The long term effects of diabetes mellitus include progressive development of the
specific  complications of  retinopathy with potential  blindness,  nephropathy that  may lead to
renal failure, and/or neuropathy with risk of foot ulcers, amputation, Charcot joints, and features
of autonomic dysfunction. People with diabetes are at increased risk of cardiovascular, peripheral
vascular and cerebrovascular disease.1
In the human body a number of systems and pathway’s function in synchrony to bring
about and maintain a healthy physiological state. At the core of these processes lies the ability of
the organism to maintain a constant stable state or homeostasis. An aberration of the homeostasis
leads to the development of an injury or a pathological state in various organs.DM reduces the
ability of an individual to regulate the level of glucose in the blood stream resulting in a number
of major some minor complications.2
2. HISTORY
Diabetes  mellitus  was  recognized  as  early as  1500  B.C.by Egyptian  physicians,  who
described a disease associated with “the passage of much urine. “The  term “diabetes”(the Greek
word  of  siphon)  was  coined  by  the  Greek  physician  Aretaeus  the  cappadocian  around
A.D.2.Aretaeus noticed that patients with diabetes had a disease that caused the siphoning of the
structural components of the body into the urine(“a melting down of the flesh limbs into the
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urine”).Although it  was known for centuries that  the urine of the patients with diabetes was
sweet,  it  was  not  until  1674  that  a  physician  named  willis  coined  the  term  “diabetes
mellitus”(from the Greek word for honey).3
3. EPIDEMIOLOGY AND PREVALENCE OF DIABETES MELLITUS.
           Epidemiology provides a scientific basis for clinical and public health practice.Indeed,
epidemiology can be used to guide how we define, diagnose, and screen for diabetes, to describe
the present and future burden of diabetes, and to highlight opportunities for intervention.4
Diabetes mellitus and its complications are now the third leading cause of death in the
United  States,  accounting  for  300,000  lives  in  each  year.  Patients  who  are  diagnosed  with
diabetes include 2.8% of the U.S. population but account for 5.8% of total personal health care
expenditures in 1992.seven to eight percent of hospital admissions are due to diabetes. A new
case of diabetes is diagnosed every 60 seconds, and the chance of developing diabetes doubles
with every 20% of excess weight and every decade of life.3
Both  the  incidence  and  prevalence  of  diabetes  increase  dramatically  with  age.  For
example, the prevalence of self-reported diagnosed diabetes is 1.7% among persons 20 to 39
years  of  age  and  15.8% among persons  over  65  years  of  age.  Onestudy estimates  that  the
prevalence of diabetes in persons over 65 years of age increased 62% from 2003 to 2004.The
prevalence of type 2 diabetes also differs among ethnic population.5
India  leads  the  world  with  largest  number  of  diabetic  subjects  earning  the  dubious
distinction of being termed the “diabetes capital of the world”. According to the diabetes atlas
2006 published by the international diabetes federation, the number of people with diabetes in
india currently around 40.9 million is expected to rise to 69.9million by 2025.6
World Health Organization to project the number of persons over the age of 20 with
diabetes in the world in the years 1995,2000,and 2025.We projected that the number of adults
with dsiabetes would increase by 42% in developed countries,from51 million to 72 million, and
170% in developing countries, from 84 million to 228 million.4
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4. CLASSIFICATION1, 7
Diabetes mellitus classified as
I. Type 1 diabetes mellitus.
A.   Immune mediated.
B.   Idiopathic.
II. Type 2 diabetes mellitus.
III. Other specific types of diabetes.
A. Genetic defects of β-cell function.
B.   Genetic defects in insulin action.
C.   Disease of the exocrine pancreas.
D. Endocrinopathies.
E.   Drug or chemical induced.
F. Infections
G. Uncommon forms immune-mediated diabetes.
H. Other genetic syndromes sometimes associated with diabetes.
IV. Gestational diabetes mellitus.               
I. TYPE 1(IDDM)1,7,8
The β-cell destruction, usually leading to absolute insulin deficiency.
   Signs and symptoms
 Polyuria, polydipsia, polyphagia, thirst.
 Weakness or fatigue.
 Weight loss associated with random plasma glucose≥200 mg/dl.
 Ketonemia, ketonuria, or both.
 Islet autoantibodies are frequently present. 
   Pathophysiology
A. Immune mediated diabetes
             This form of diabetes, which accounts for only 5-10% of those with diabetes,
previously encompassed by the terms insulin dependent diabetes, type I diabetes, or juvenile-
onset  diabetes,  results  from a cellular-mediated auto immune destruction of  the pancreas.
Markers of the immune destruction of the cell include islet cell autoantibodies, autoantibodies
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to insulin, autoantibodies to glutamic acid decarboxylase (GAD65) and auto anti bodies to the
tyrosine  phosphatases  IA-2  and  IA-2β.one  and  usually  more  of  these  autoantibodies  are
present in 85-90% of individuals when fasting hyperglycemia is initially detected. Also the
disease has  strong HLA association,  with  linkage to  the DQA and  DQB genes,  and it  is
influenced  by the  DRB genes.  These  HLA-DR/DQ alleles  can  be  either  predisposing  or
protective. 
In this form of diabetes, the rate of-cell destruction is quite variable, being rapid in some
individuals (mainly infants and children) and slow in others (mainly adults).some patients,
particularly children and adolescents, may present with ketoacidosis as the first manifestation
of the disease. Such individuals eventually become dependent on insulin for survival and are
at risk for ketoacidosis. At this later stage of the disease, there is little or no insulin secretion
as manifested by low or undetectable levels of plasma C-peptide. Immune mediated diabetes
commonly occurs in childhood and adolescence, but it can occur at any age, even in the 8th
and 9th decades of life.
           Autoimmune destruction of β-cells has multiple genetic predispositions and is also
related to environmental factors that are still poorly defined.
B. Idiopathic diabetes
Some forms of type 1 diabetes have no known etiologies. Some of these patients have
permanent  insulinopenia  and  are  prone  to  ketoacidosis,  but  have  no  evidence  of
autoimmunity.  Although  only  a  minority  of  patients  with  type  1  diabetes  fall  into  this
category, of those who do, most are of African or Asian ancestry. Individuals with this form of
diabetes suffer from episodic ketoacidosis and exhibit varying degrees of insulin deficiency
between episodes. This form of diabetes is strongly inherited lacks immunological evidence
for  β-cell  auto immunity,  and is not  HLA associated.  An absolute requirement for insulin
replacement therapy in affected patients. 
II.   TYPE 2(INDDM)
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May  range  from  predominantly  insulin  resistance  with  relative  insulin  deficiency  to  a
predominantly insulin secretory defect with insulin resistance.
   Signs and symptoms
 Polyuria and thirst.
 Weakness or fatigue.
 Recurrent blurred vision.
 Vulvovaginitis or pruritus.
 Peripheral neuropathy.
 Often asymptomatic.8
Pathophysiology
This form of diabetes,  which accounts for  90-95% of those with diabetes,  previously
referred to as  non-insulindepedent diabetes, or adult-onset diabetes, encompasses individuals
who have insulin resistance and usually have relative(rather than absolute)insulin deficiency
At least initially, and often throughout their life time, these individuals do not need insulin
treatment  to  survive.  There  are  probably many different  causes  of  this  form of  diabetes.
Although the specific etiologies are not known, autoimmune destruction of β-cells does not
occur, and patients do not have any of the other causes of diabetes listed above or below.7
Most  individuals  with  type  2  diabetes  exhibit  abdominal  obesity  which  itself  causes
insulin resistance. In addition, hypertension, dyslipidemia (high triglycerides levels and low
HDL-cholesterol  levels),  and  elevated  inhibitor  plasminogen  activator-1(PAI-1)  levels  are
often  present  in  these  individuals.  This  clustering  of  abnormalities  is  referred  to  as  the
“insulin resistance syndrome” or the metabolic syndrome. “Because of these abnormalities,
patients with type 2 diabetes are at increased risk of developing macrovascular complications.
Type 2 diabetes has a strong genetic cause of most cases of type 2 diabetes.9
III. OTHER SPECIFIC TYPES.1, 7
A. Genetic defects of β-cell function.
 Chromosome 12,HNF-1α(MODY3)
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 Chromosome 7,glucokinase(MODY2)
 Chromosome 20,HNF-4α(MODY1)
 Chromosome 13,insulin promoter factor-1(IPF-1;MODY4)
 Chromosome 17,HNF-1β(MODY5)
 Chromosome 2,NeuroD1(MODY6)
 Mitochondrial DNA
B. Genetic defects in insulin action.
 Type A insulin resistance.
 Leprechaunism
 Rabson-Mendenhall syndrome
 Lipoatrophic diabetes
C. Diseases of the exocrine pancreas.
 Trauma/pancreatectomy
 Pancreatitis
 Neoplasia
 Cystic fibrosis 
 Hemochromatosis 
 Fibrocalculouspancreatopathy
D. Endocrinopathies.
 Acromegaly 
 Cushing’s syndrome
 Glucagonoma
 Pheochromocytoma
 Hyperthyroidism 
 Somatostatinoma
 Aldosteronoma
E. Drug-or chemical-induced.
 Vacor
 Pentamidine
 Nicotinic acid
 Glucocorticoids 
 Thyroid hormones
 Diazoxide
 β-adreneergic agonist
 Thiazides
 α-interferon
F. Infections 
 Congenital rubella
 Cytomegalo virus
G. Uncommon forms of immune-mediated diabetes.
 “stiff-man”syndrome
 Anti-insulin receptor antibodies
H.  Other genetic syndromes sometimes associated with diabetes.
 Down’s syndrome
 Klinefelter’s syndrome
 Turner’s syndrome 
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 Wolfram’s syndrome
 Friedreich’s ataxia
 Huntington’s chorea
 Laurence-moon-biedl syndrome
 Myotonic dystrophy
 Porphyria
 Prader-Willi syndrome
IV. Gestational diabetes mellitus.
GDM is defined as any degree of glucose intolerance with onset or first recognition 
during pregnancy.
DIAGNOSIS (OR) SCREENING METHOD
The term diagnosis refers to confirmation of diabetes in people who have symptoms, or
who have had a positive screening test.  In diabetes, the screening test may be the diagnostic
test.10
Diagnosis of diabetes is done by measuring blood/plasma glucose level.1
Oral Glucose Tolerance Test (OGTT):
The test should be preceded by an overnight fast of 8-14 hours, a morning fasting blood
sugar is drawn and patients ingest a 75g glucose load.  Then blood samples are drawn at half an
hour intervals for 2 hours and then at 3 hours.  In normal subjects, the blood glucose returns to
normal in less than 2 hours.  The normal and up normal OGTT are1
2-Hour post load plasma glucose (oral glucose tolerance test)
Normal =<140mg/dL (7.8mmol/L)
Impaired glucose tolerance (IGT) =140-199mg/dL (7.8-11.1 mmol/L)
Diabetes mellitus =≥200mg/dL(11.1 mmol/L)9
Fasting plasma glucose (FPG):
Blood is drawn from the overnight fast.  The diagnosis of diabetes mellitus may be confirmed in
the patient with two or more fasting plasma glucose levels.1
Fasting plasma glucose (FPG)
Normal =FPG<100 mg/dL (5.6 mmol/L)
Impaired glucose tolerance (IGT) =100-125 mg/dL (5.6-6.9 mmol/L)
Diabetes mellitus =FPG ≥126mg/dL(7.0 mmol/L)9
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Glycosylated hemoglobin (HbA1c)
Glycated hemoglobin (AIC) is a valuable indicator of treatment effectiveness, and should
be measured every 3 months when glycemic targets are not being met and when diabetes therapy
is being adjusted.  HbA1C is a reliable estimate of mean plasma glucose (PG) levels over the
previous 3 to 4 months for most individuals.11
Since  glycation  of  hemoglobin  occurs  only  as  the  erythrocyte  circulates  in  serum,
hemoglobin in the older erythrocytes is more glycosylated; hemoglobin in the reticulocyte is less.
Total HbA1c reflects them is of older and younger erythrocytes.  Therefore, if the average life of
red cells is abnormally short.12Glycemic control is defined as if the measured HbA1c; 13
COMPLICATIONS 
Diabetes is associated with an increased risk of developing vascular complications that
contribute to morbidity and mortality of patients.  Poor glycaemic and blood pressure control
lead to vascular complications that affect large (macrovascular), small (microvascular) vessels,
or both.2
The importance of protecting the body from hyperglycemia cannot be overstated;  the
direct and indirect effects on the human vascular tree are the major source of morbidity and
mortality in both type 1 and type 2 diabetes.  Generally, the injurious effects of hyperglycemia
are  separated  into  macrovascular  complications  (coronary  artery  disease,  peripheral  arterial
disease  and  stroke)  and  microvascular  complications  (diabetic  nephropathy,  neuropathy,  and
retinopathy)14
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Hyperglycemia is considered a major factor in the development of diabetic complications
and  the  adverse  effects  are  recognizable  through  multiple  pathways.   The  aldose  reductase
(polyol) pathway, advanced glycation end-product pathway, hexosamine pathway, and protein
kinase C pathway provide evidence that elevated blood glucose promotes cellular dysfunction
and damage.15
MICROVASCULAR COMPLICATIONS 
Microvascular complications involve damage to the small blood vessels and contribute to
diabetic  neuropathy  (nerve  damage,),  nephropathy  (kidney  disease)  and  retinopathy  (eye
disease).2
In fact,  macrovascular complications can begin developing at least  7 years before the
clinical diagnosis of type 2 diabetes.15
Diabetic Retinopathy 
Diabetic retinopathy, caused by damage to the retinal vasculature, is a common cause of
blindness and visual  impairment in the working age population.   The occurrence of diabetic
retinopathy can be reduced and / or prevented by adequate and timely treatment.2
Development of diabetic retinopathy in patients with type 2 diabetes was found to be
related to both severity of hyperglycemia and presence of hypertension in the U.K.14
Aldose  reductase  pathway  involves  the  conversion  of  glucose  into  glucose  alcohol
(sorbitol).  High glucose levels increase the flux of sugar molecules through the polyol pathway,
which causes sorbitol accumulation in cells.  Osmotic stress from sorbitol accumulation has been
postulated as an underlying mechanism.14
Early detection and timely treatment of diabetic retinopathy can prevent loss of vision.
Many people are not receiving recommended eye care for diabetic retinopathy.  Various public
health programs have been developed to overcome barriers to optimal eye care.16
Diabetic Neuropathy
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Diabetic neuropathy classified as peripheral, proximal, focal and autonomic, is the most
common of all the log-term complications of diabetes, with nearly 60% of patients having some
form of nerve damage. It is a progressive disease that involves loss of sensation, as well as pain
and weakness, and can lead to limb amputations.2
Physical  examination  reveals  sensory loss  to  light  touch,  vibration,  and  temperature.
Abnormalities in more than one test of peripheral sensation are >87% sensitive in detecting the
presence of neuropathy.14
Diabetic Nephropathy 
Diabetic nephropathy is the leading cause of end – stage renal disease (ESRD) and the
most  common  cause  for  kidney transplantation  in  the  developed  world.   The  presence  and
progressive  rise  of  albumin  in  urine  along  with  elevated  glomerular  blood  pressure  are  the
biomarkers of nephropathy.  In the absence of appropriate intervention, the condition persists and
leads  to  the  loss  of  protein  in  urine  and  a  decline  in  renal  function  in  the  form of  lower
glomerular filtration rate.  This eventually leads in ERSD and complete renal failure.  Clinical
evidence suggests that approximately 15-20% of patients with T1DM and 30-40% with Type 2
develop ESRD.2
Microalbuminuria  is  defined  as  albumin  excretion  of  30-299  mg/24  hours.   Without
intervention, diabetic patients with microalbuminuria typically progress to proteinuria and overt
diabetic nephropathy.14
MACROVASCULAR COMPLICATIONS 
The macrovascular complications, which affect the large vessels of the circulatory system
may lead in 2 to 4 times higher incidence of stroke (cerebrovascular), coronary heart disease
(CHD)  and  peripheral  vascular  disease  which  can  lead  to  ulceration,  gangrene  and  lower
extremity amputations. These macrovascular complications are essentially accelerated forms of
atherosclerosis involving the migration of leukocytes to site of arterial injury.2
The risk of macrovascular complications is increased by other factors such as arterial
hypertension,  dyslipoproteinaemia  or  obesity,  which  are  frequently  associated  with  diabetes.
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These  ‘risk  factors’ have  both  genetic  and  environmental  backgrounds,  which  contribute  to
accelerated manifestation of cardiovascular disease.17
The central pathological mechanism inmacrovascular disease is the process of atherosclerosis,
which leads to narrowing of arterial walls throughout the body.  Atherosclerosis is thought to
result from chronic inflammation and injury to the arterial wall in the peripheral or coronary
vascular system.14
Cardiovascular: 
People  with  diabetes  are  2  to  4  times  more  likely to  develop  cardiovascular  disease
(CVD) than those without diabetes. However; the risk of coronary artery disease is increased in
patients with poor glycemic control.  In  patients with insulin resistance,  the disease tends to
accelerate to atherogenesis long before the onset of hyperglycemia.  There are several risk factors
that  may contribute to the development of  coronary heart  disease (CHD),  including lifestyle
(e.g., cigarette smoking and diet), hyperglycemia, hypertension, and high cholesterol.15
Cerebrovascular:
Cerebrovascular disease is a term encompassing many dis orders that affect the blood
vessels of the central nervous system.  These disorders result from either inadequate blood flow
to the brain (i.e. cerebral ischemia) or from hemorrhages into the parenchyma or subarachnoid
space  of  the  central  nervous  system  (CNS).   Various  terms  have  been  used  to  describe
cerebrovascular events.  For example, the term transients ischemic attack (TIA).15
Peripheral Arterial Disease (PAD): 
Peripheral arterial disease (PAD) is an atherosclerotic occlusive disease.  It is the major
risk  factor  for  lower  extremity  amputations.   The  abnormal  metabolic  state  accompanying
diabetes results in changes in the state of arterial structure and function predisposing people.15
Elevated levels of C-reactive protein (CRP), fibrinogen, homocysteine, apolipoprotein B,
lipoprotein (a), and plasma viscosity are potential risk factors for PAD.15
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The  2  Cardinal  symptoms  of  PAD  are  intermittent  claudication  and  pain  at  rest.
Intermittent claudication is characterized by pain, ache, a sense of fatigue, or other discomfort
that occurs in the affected leg during exercise, particularly walking, and resolves with rest.15
MANAGEMENT OF DIABETES 
The main aim in the management of diabetes is to maintain blood glucose levels as near
to normal as possible, while avoiding hypoglycaemia.  In order to achieve this, there are five
tools  involved  in  diabetes  treatment  which  are  education,  exercise  /  activity,  diet,  oral
medications and or insulin, often used in combination.2
The primary goals of DM management are 
To reduce the risk for microvascular and macrovascular disease complications.
To ameliorate symptoms.
To reduce mortality.
 To improve quality of life.9
The goal achieved by non-pharmacological and pharmacologic management. 
NON PHARMACOLOGIC THERAPY
Self-management education (SME):
Self-management education (SME) that incorporates knowledge and skills development,
as well as cognitive behavioral interventions, should be implemented for all individuals with
diabetes.  The content of SME programs must be individualized according to the individual’s
type of diabetes, current state of metabolic stability, treatment recommendations, readiness for
change, learning style, ability, resources and motivation.
SME is a fundamental component of diabetes care and is most effective when ongoing
diabetes education and comprehensive healthcare occur together.18
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Make patient-centered, structured self-management education an integral part of the care
of all people with type 2 diabetes.19
Role of clinicians in promoting self-care is vital and has to be emphasized.  Realizing the
multifaceted nature of the problem, a systematic, multi-pronged and an integrated approach is
required  for  promoting  self-care  practices  among  diabetic  patients  to  avert  any  long-term
complications.20
Dietary management: 
Dietary management involves controlling weight and the introduction of a healthy dieting
plan.  Healthy dieting is a critical component in the management of type 1 and type 2 diabetes.
In over 50% of people presenting with type 2 diabetes retraction of energy intake, increased
activity and weight reduction will initially normalize blood glucose, Diabetes Management in
General Practice levels.  Medication is likely to be needed later. While an appreciation of the
dietary management of diabetes by the general practitioner or physician is important, detailed
instructions need to be given by a dietitian.21
Nutrition therapy can reduce glycated hemoglobin by 1.0 to 2.0% and, when used with
other  components  of  diabetes  care,  can  further  improve  clinical  and  metabolic  outcomes.
Consistency in carbohydrate intake, and spacing and regularity in meal consumption may help
control  blood  glucose  and  weight.   Replacing  high-glycemic  index  carbohydrates  with  low
glycemic index carbohydrates in mixed meals has  a clinically significant  effect  on glycemic
control in people with type 1 or type 2 diabetes.22
Physical activity: 
Regular physical activity improves metabolic control and reduces other cardiovascular
risks in people with diabetics.  Low level aerobic exercise (e.g.: brisk walking for half an hour
per day) and in the absence of contraindications, encourage performance of resistance training at
least three times per week.  Physical resistance training have the following benefits.23
  Improved glucose tolerance as insulin sensitivity increases 
  Increased energy expenditure resulting in weight loss 
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 Increased feeling of well being 
 Increased work capacity 
 Improved blood pressure and lipid profiles.21
Moderate to high levels of physical  activity and cardiorespiratory fitness are associated with
substantial reductions in morbidity and mortality in both men and women and in both type 1 and
type 2 diabetes.24
PHARMACOLOGIC MANAGEMENT 
Anti-diabetic agent: 
Multiple  inventions  and  medications  are  needed  to  control  the  multiple  risk  factors
associated  with  type  2  diabetes  (hyper  glycaemia,  hypertension,  dyslipidemia  and  increased
thrombogenesis).21
There are six classes of oral agents are approved for the treatment of type 2 diabetes:
α-glucosidase  inhibitors,  biguanides,  meglitinides,  peroxisome  proliferator  activated  receptor
β-agonists  (Which  are  also  commonly  identified  as  thiazolidinediones  or  glitazones),
sulfonylureas, incretin and gliptins. Oral agents are indicated for use in type 2 DM patients who
are unable to achieve glycemic control goals despite diet and exercise.  Oral antidiabetic agents
are often grouped according to their glucose-lowering mechanism of action.  Biguanides and
thiazolidinediones are often categorized as insulin sensitizers due to their ability to reduce insulin
resistance.  sulfonylureas and meglitinides are often categorized as insulin secretagogues because
they enhance endogenous insulin release.9
Sulfonyl ureas: 
Sulfonylureas  are  classified  as  first-generation  and  second-generation  agents.   First-
generation  agents  consist  of  acetohexamide,  chlorpropamide,  tolazamide,  and  tolbutamide.
Each of these agents is lower in potency relative to the second-generation drugs: glimepiride,
glipizide, and glyburide.  The primary mechanism of action of sulfonylureas is enhancement of
insulin secretion.  Sulfonylureas bind to a specific sulfonylurea receptor (SUR) on pancreatic β
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cells.  Binding closes an adenosine triphosphate – dependent K+ channel, leading to decreased
potassium influx  and  subsequent  depolarization  of  the  membrane.   Voltage-dependent  Ca+2
channels  open  and  allow  and  inward  flux  of  Ca+2.  Increases  in  intracellular  Ca+2  cause
translocation of secretory granules of insulin to the cell surface and resultant exocytosis of the
granule of insulin.  Elevated secretion of insulin from the pancreas travels via the portal vein and
subsequently suppresses hepatic glucose production.9
All sulfonylureas are equally effective in lowering blood glucose when administered in
equipotent doses.  The recommended starting doses should be reduced in elderly patients who
may have compromised renal or hepatic function.  Dosage can be titrated every 1 to 2 weeks
(longer interval with chlorpropamide) to achieve glycemic goals.  On average, the HbA1c will
fall by 1.5% to 2% with FPG reductions of 60 to 70 mg/dL.  The most common side effect is
hypoglycemia;  Weight  gain  is  common;  less  common  adverse  effects  include  skin  rash,
hemolytic anemia, gastrointestinal upset and cholestasis.  Hyponatremia is most common with
chlorpropamide but has also been reported with tolbutamide;9
Biguanides: 
In most of the world, metformin is the only biguanides available.  Its major effect is to
decrease  hepatic  glucose  output  and  lower  fasting  glycaemia.25Metformin  enhances  insulin
sensitivity of both hepatic and peripheral (muscle) tissues.  This allows for an increased uptake
of  glucose  into  these  insulin-sensitive  tissues.   The  exact  mechanisms  of  how  metformin
accomplishes  insulin  sensitization  are  still  being  investigated,  though  adenosine  5’-
monophosphate-activated  protein  kinase  activity,  tyrosine  kinase  activity  enhancement,  and
glucose transporter 4 all play a part.  Metformin has no direct effect on the β cells, though insulin
levels are reduced, reflecting increases in insulin sensitivity.9
Clinical trials have documented that metformin therapy consistently decreases the fasting
plasma glucose level by 3.3 to 3.9 mmol/L (60 to 70 mg/dL) and the HbA1c value by 1.5 to 2.0
percentage points in patients with poorly controlled diabetes.26
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Metformin causes gastrointestinal side effects, including abdominal discomfort, stomach
upset, and/or diarrhea in approximately 30% of patients.  Anorexia and stomach fullness is likely
part of the reason loss of weight is noted with metformin.9
Thiazolidines: 
Thiazolidinediones  are  also  referred  to  as  TZDs  or  glitazones.  Pioglitazone  and
rosiglitazone are the two currently approved thiazolidinediones for the treatment of type 2 DM.
Thiazolidinediones work by binding to the peroxisome proliferator activator receptor-γ  (PPAR-γ
), which are primarily located on fact cells and vascular cells.9 Like the sulfonylureas, theglinides
stimulate insulin secretion, although they bind to a different site within the sulfonylurea receptor.
Decreasing A1C levels by-1.5 percentage points.  The risk of weight gain is similar to that for the
sulfonylureas, but hypoglycemia may be less frequent.25
α-Glucosidase inhibitor: 
α-Glucosidase  inhibitors  competitively inhibit  enzymes  (maltase,  isomaltase,  sucrose,
and  glucoamylase)  in  the  small  intestine,  delaying  the  breakdown  of  sucrose  and  complex
carbohydrates.   They do not cause any malabsorption of these nutrients.   The net effect from
this action is to reduce the postprandial blood glucose rise.9 Reducing A1C levels by 0.5 – 0.8
percentage  points.25The  gastrointestinal  side  effects,  such  as  flatulence,  bloating,  abdominal
discomfort, and diarrhea, are very common and greatly limit the use of α- glucosidase inhibitors.9
Insulin: 
Insulin  may be  required  if  adequate  control  has  not  occurred  on  maximum does  of
hypoglycemic agents.  However, ensure that exercise and dietary management are satisfactory
and  exacerbating  factors  e.g.:  intercurrent  infection,  problems  with  medication  has  been
excluded.  Insulin may be needed early in the condition when treatment is being started (the so-
called ‘primary’ failure of oral hypoglycemic agents that suggests the patient actually has type I
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diabetes) or when the patient has later become refractory to oral hypoglycaemic agents (so-called
‘secondary’ failure consistent with the usual progression of type 2 diabetes). If  the patient  is
symptomatic then insulin is required.  If there are no symptoms but fasting blood glucose levels
are consistently > 7.0 mmol/L, the decision is more difficult.  When deciding glycaemic targets
and  considering  insulin  treatment,  take  into  account:  life  expectancy,  existing  physical  and
psychosocial problems and potential problems with insulin.  The selection of treatment goals,
treatment schedules and monitoring schedules needs to be a decision arrived at after discussion
with the patient and may be the stimulus for a General Practice Management Plan.  Initiation of
treatment with insulin is regarded as a major step by most patients.  They require encouragement
and psychological support.  At this stage the help of a physician with a special interest in diabetes
may useful.  People with type 2 diabetes requiring insulin can often be managed with a singly
daily dose of intermediate or long acting insulin added to their oral hypoglycaemic schedule.21
Incretin-Based Therapies:
Glucagon-like peptide-1(GLP-1):
Incretin mimetics are new class of antidiabetic agents first introduced in the years 2005
(exenatide)  and liraglutide,  respectively.   Both use the  antidiabetic  properties  of  the incretin
hormone, glucagon-like peptide (GLP)-1 a naturally occurring peptide produced by the L-cells of
the small intestine, potentiates glucose-stimulated insulin secretion.27
When meals are consumed, the GI tract releases a number of hormones that aid in the
absorption and disposition of nutrients.  Among these, the hormones glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide (GIP) are of particular importance
because  of  their  regulation  of  islet  hormone  secretion.   GLP-1  and  GIP augment  glucose-
stimulated insulin secretion, a process termed the incretin effect.  The incretin effect account for
approximately 50% of the insulin secreted after meals and therefore has a prominent role in
postprandial metabolism.  Incretin signaling is essential for normal glucose tolerance. In addition
to stimulating insulin secretion; GLP-1 also inhibits glucagon secretion.  Importantly, the incretin
effect is impaired in subjects with T2DM, and this likely contributes to the abnormal control of
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postmeal glucose levels that is a hall mark of this condition it decreases body weight and also
inhibit the glucagon production.28
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Figure 1- The Schematic diagram explaining the physiological (postprandial) secretion of GLP-
1 from the gut, its binding to GLP-1 receptors (e.g., on pancreatic endocrine_-cells), and its
degradation by the ubiquitous protease DPP-4 as well as its rapid renal elimination (A). Incretin
mimetics are peptide GLP-1 receptor agonists more or less structurally similar to GLP-1, which
bind and activate the GLP-1 receptor, but are not degraded by DPP-4 and have much slower
elimination pharmacokinetics (B). DPP-4 inhibitors prevent the degradation/inactivation of the
biologically  active  form  of  GLP-1  and,  thereby,  augment  the  biological  activity  of  GLP-1
released from endogenous sources (C).27
Dipeptidyl peptidase four inhibitors. (DPP-4)
The  DPP-4  inhibitors  are  the  newest  class  of  oral  antihyperglycemic  agents  also
commonly called gliptins.  GLP-1 and glucose-dependent insulinotropic peptide (GIP), the main
insulinotropic  peptides  of  intestinal  origin  (incretins),  are  rapidly  degraded  by  dipeptidyl
peptidase four (DPP-4).  DPP-4 is  a member of a family of cell  membrane proteins  that  are
expressed in many tissues, including immune cells.  DPP-4 inhibitors are small molecules that
enhance  the  effects  of  GLP-1  and  GIP,  increasing  glucose-mediated  insulin  secretion  and
suppressing glucagon secretion.25
The overall experience with DPP-4 inhibitions therefore that they are orally active, safe,
and highly tolerable,  with a minimal risk for hypoglycemic events.   Furthermore,  they show
sustained, robust, and clinically significant improvement in glycemia in both monotherapy and
combination  with  metformin  and  thiazolidinediones,  and  they are  bodyweight  neutral.   The
relevant mechanisms of action of DPP-4 inhibition (mainly improvement of islet function) and
the efficacy, tolerability, and safety of treatment suggest that this approach has great potential as
a novel treatment.  
The clinical trials with gliptinshave measured fasting levels of lipids, and in general no or
very little effects have been found on parameters such as cholesterol and triglycerides.   This
would suggest that DPP-4 inhibition does not affect lipid metabolism. 
Results presented thus far suggest that DPP-4 inhibition has its strongest potential as a
first-line  treatment  in  early  stages  of  type  2  diabetes  in  combination  with  metformin  and
thiazolidinediones.  DPP-4 inhibitors are also strong candidates for being established as a first-
line  treatment  as  monotherapy,  particularly  in  elderly  subjects  and  in  subjects  with
contraindication or intolerance for metformin or thiazolidinediones.  DPP-4 inhibition may also
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be used  in  combination with  insulin  with  the  great  advantage  of  reducing the  likelihood  of
developing hypoglycemia.  Whether DPP-4 inhibition may also be advantageous over existing
treatment  in  long  term  therapy  of  more  advanced  stages  of  the  disease  remains  to  be
established.29
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Maximilion  von Eynatten,  et  al.  (2013) in  patients  with  type  2 diabetes  mellitus  (T2DM),
hypertension and microalbinuria are predictive markers for increased renal and cardiovascular
risk. This post hoc analysis of data from a global development program aimed to evaluate the
efficacy and safety of Linagliptin in a population with joint prevalence of these two vascular risk
factors. Data for patients with baseline micro albuminuria (urine albumin-to-creatinine ratio 30-
300mg/g)  and  hypertension  (systolic  blood  pressure≥140mm  Hg  and/or  diastolic  blood
pressure≥90 mm Hg and /or a history of hypertension; and/or an antihypertensive treatment at
baseline) who participated in any of six randomized, placebo-controlled, phase III trials were
analyzed. Participants received Linagliptin 5mg daily (alone or in combination with other oral
anti diabetic drugs) or placebo for 18 to 24 weeks. In T2DM patients with the two common
vascular  risk factors of hypertension and micro albuminuria,  Linagliptin achieved significant
improvements in glycemic control. In this vulnerable patient population at high risk for micro-
and macro vascular complication, linagliptin was well tolerated.
Janet  B.  McGill,  et  al.(2013)  the  placebo-  controlled  study assessed  long-termefficacy and
safety of the dipeptidyl  peptidase-4 inhibitor linagliptin in patients with  type 2 diabetes  and
severe  renal  impairment(RI).In  this  1-year,double  blind  study,133  patients  with  type  2
diabetes(HbA1c  7.0-10.0%)  and  severe  RI  (estimated  glomerular  filtration  rate  [eGFR]
30ml/min/1.73m2)  at  screening were  randomized  to  Linagliptin  5mg(n=68)  or  placebo(n=65)
once daily,  added to existing backround therapy. The primary efficacy end point was HbA1c
change from baseline to week 12.Efficacy and safety end points were assessed after 1 year. In
patients  with  type  2  diabetes  and  severe  RI,  Linagliptin  provided  clinically  meaningful
improvements  in  glycemic  control  with  very low risk  of  severe  hypoglycemia,  stable  body
weight, and no cases of drug related renal failure. The potential for Linagliptin to spare insulin
and provide long-term renal safety warrants further investigations. 
Odd Erik Johansen, et al.(2012) this study investigated the cardiovascular safety profile of the
dipeptidyl peptidase(DPP)-4 inhibitor Linagliptin versus comparator treatments. This was a pre-
specified meta-analysis of CV events in Linagliptin or comparator-treated patients with type 2
diabetes mellitus (T2DM) from eight phase 3 studies. All suspected CV events were adjudicated
by a blinded independent expert committee. The primary end point was a composite of CV death,
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stroke,  myocardial  infarction,  and  hospitalization  for  unstable  angina.  Three  secondary
composite  end points  derived from the adjudicated  CV events  were  also pre-specified.  Risk
estimates were calculated using several  statistical methods including cox regression analysis.
These results from a large phase 3 programme support the hypothesis that linagliptin may have
CV benefits in patients with T2DM.
Debmalya sanyal, et al. (2013) new-onset diabetes after transplantation (NODAT) is frequently
encountered after kidney transplant. In the present study, we retrospectively evaluated the safety
and efficacy of Linagliptin monotherapy in 21 renal transplant recipients in a real world setting.
We  found  Linagliptin  monotherapy  is  effective  for  glycemic  control  in  NODAT,even  on
glucocorticoids  and  standard  dose  of  tacrolimus.There  was  no  alteration  of  tacrolimus  drug
levels or estimated glomerular filtration rate and minimal side effects, including weight gain and
hypoglycemia.well-designed,powered randomized controlled of antiglycemic agents in NODAT
are needed.
Erica paniago guedes, et al. (2013) linagliptin: farmacology, efficacy and safety in the type 2
diabetes treatment. Type 2 diabetes patients have dysfunction in incretin hormones (as glucagon-
like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP).By inhibiting
the dipeptidyl pepdidase-4(DPP-4) enzyme; it is possible to slow the inactivation of GLP-1 and
GIP, promoting blood glucose level reduction in a glucose-dependent manner. Linagliptin is a
highly specific and potent inhibitor of DPP-4 that is currently indicated for the treatment of type2
diabetes.  Clinical  studies  with  Linagliptin  demonstrated  efficacy  in  reducing  glycated
haemoglobin (HbA1c) levels in type 2 diabetes patients, while maintaining a placebo-like safety
and tolerability profile.  Linagliptin has an interesting pharmacokinetic  profile  in terms of  its
predominantly non-renal elimination and the main implication of this characteristic is that no
dose adjustment is necessary in patients with renal disease. Also, no dose adjustment is required
in patients with hepatic insufficiency, as well in elderly or obese patients. This article will review
the pharmacokinetic profile, efficacy data and safety aspects of Linagliptin in type 2 diabetes
patients. 
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Hannele Yki-jarvinen, et al. (2013) evaluates the effects of adding Linagliptin to basal insulin
regimen  for  inadequately  controlled  type  2  diabetes.  A  total  of  1,261  patients
(HbA1c≥7.0%[53mmol/mol]to≤10.0%[86mmol/mol])on basal  insulin  alone or  combined  with
metformin and/or pioglitazone were randomized(1:1)to double-blind treatment with Linagliptin
5mg once daily or placebo for≥52 weeks. The basal insulin dose was kept unchanged for 24
weeks  but  could  thereafter  be  titrated  according  to  fasting  plasma  glucose  levels  at  the
investigators discretion. The primary end point was the mean change inHbA1c from baseline to
week 24.the safety analysis incorporated data up to a maximum of 110 weeks. Linagliptin added
to  basal  insulin  therapy significantly improved  glycemic  control  relative  to  placebo  without
increasing hypoglycemia or body weight.  
Barry J.Goldstein, et al. (2007)   assess the efficacy and safety of initial combination therapy
with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control
on  diet  and  exercise.  In  a  24-week,randomized,double-blind,placebo-controlled,parallel-group
study,1091 patients with type 2 diabetes and HbA1c 7.5-11% were randomized to one of six
daily  to  the     treatment:sitagliptin100mg/metformin1000mg(S100/M1000group),sitagliptin
100mg/metformin2,000mg  (S100/M2000  group),metformin1000mg(M1000  group),metformin
2,000mg(M2000 group)(all as divided doses administered twice daily [b.i.d] ) sitagliptin100mg
q.d  (S100  group),or  placebo.  Patients  who  had  an  HbA1c  >11%  or  a  fasting  glucose
value>280mg/dl after the run- in period were not eligible to be randomized; these patients could
participate in an open-label sub study and were treated with S100/M2000 for 24 weeks. The
initial  combination  of  sitagliptin  and  metformin  provided  substantial  and  additive  glycemic
improvement and was generally well tolerated in patients with type 2 diabetes. 
Carolina  Solis-Herrera,  et  al.(2013)  assess  mechanism  of  glucose  lowering  of
sitagliptin(S),metformin(M) and two combined (M+S) in type 2 diabetes.  We randomized 16
patients  with  type  2  diabetes  mellitus(T2DM)  to  four  6-week  treatments  with
placebo(P),M,S,andM+S.After each period,  subjects received a 6-h meal tolerance test(MTT)
with[14  C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma
insulin,  C-peptide  (insulin  secretory  rate  [ISR]),  fasting  plasma  glucagon,  and  bioactive
glucagon-like  peptide  (GLP-1)  and  gastrointestinal  insulinotropic  peptide  (GIP)  were
measured.M+S  combined  produce  additive  effects  to;  reduce  FPG  and  post  meal  glucose,
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augment GLP-1 secretion and b-cell function, decrease plasma glucagon, and inhibit fasting and
post meal EGP compared with M or S monotherapy.
Guillermo  E.  Umpierrez,  et  al.  (2013)  this  study  investigated  the  safety  and  efficacy  of
sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine
and surgery patients.  In  this pilot,  multicenter,  open-label, randomized study, patients (n=90)
with a known history of T2D treated with diet, oral anti diabetic agents, or low total daily dose of
insulin (≤0.4 units/kg/day) were randomized to receive sitagliptin alone or in combination with
glargine  insulin  (glargine)  or  to  a  basal  bolus  insulin  regimen  (glargine  and  lispro)  plus
supplemental (correction) doses of lispro. Major study outcomes included differences in daily
blood  glucose  (BG),  frequency  of  treatment  failures  (defined  as  three  or  more  consecutive
BG>240mg/dl or a mean daily BG>240mg/dl), and hypoglycemia between groups. Results of
this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe
and effective for the management of hyperglycemia in general medicine and surgery patients
with T2D. 
Jorge Luiz Gross, et al. (2013) A novel model- based meta-analysis to indirectly estimate the
comparative  efficacy of  two medication:  an  example  using DPP-4  inhibitors,  sitagliptin  and
linagliptin,in treatment of type 2 diabetes mellitus. 
Kaustubh Nisal,et al. (2012) type 2 diabetes mellitus is widely prevalent and is often coexistent
with  obesity.  Many of  the available treatment  options  have side effects  such as weight  gain
which often affect patient’s willingness to continue the treatment. Effective weight loss, lack of
significant hypoglycaemia, and favorable cardiometabolic profile make incretin based therapies
an attractive treatment option for type 2 diabetes. Incretin based therapies are available as either
incretin mimetics(also called GLP-1 agonists)or incretin enhancers (DPP-4 inhibitors).Although
agents in both these classes of incretin based therapy are effective through a common GLP-1
pathway,  there  are  many  differences  amongst  them  including  the  route  of  administration,
frequency of administration, effects on body weight, extent of glycaemic improvement. There are
several  trials  evaluating  these  individual  incretin  based  agents  either  as  monotherapy  or  in
combination  with  other  anti-diabetic  agents,  however  very  few  have  looked  into  direct
comparison amongst the agents in these two classes. This review is aimed to look at important
mechanistic  differences  between  incretin  mimetics  and  enhancers  through  direct  comparison
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trials  and  impact  of  these  differences  on  biochemical,  metabolic  and  patient  satisfaction
parameters. 
Masaya Sakamoto,et al.(2012)  assess the comparison of vildagliptin twice daily vs. sitagliptin
once  daily  using  continuous  glucose  monitoring(CGM).twenty patients  with  type  2  diabetes
mellitus were randomly allocated to groups who received vildagliptin then sitagliptin, or vice
versa. Patients were hospitalized at 1 month after starting each drug, and CGM was used to
determine: mean(±standard deviation) 24-hour blood glucose level, mean amplitude of glycemic
excursions(MAGE),fasting blood glucose level, highest post prandial blood glucose level and
time,  increase in  blood glucose  level  after each meal,  area under  the curve(AUC) for  blood
glucose level≥180mg/dl  within 3  hours after  each meal,  area over  the curve(AOC) for daily
blood glucose level<70mg/dl,plasma glycosylated hemoglobin(HbA1c),glycoalbumin(GA),1,5-
anhydroglucitol(1,5AG),immunoreactive  insulin(IRI),C-peptide  immunoreactivity(CPR),brain
natriuretic peptide(BNP),and plasminogen activator inhibitor-1(PAI-1) levels, and urinary CPR
levels, were measured.CGM showed that mean 24-h blood glucose,MAGE,highest blood glucose
level after supper, and hyperglycemia after breakfast were significantly lower in patients with
type  2  diabetes  mellitus  taking  vildagliptin  than  those  taking  sitagliptin.  There  were  no
significant  differences  in  BNP  and  PAI-1  levels  between  patients  taking  vildagliptin  and
sitagliptin.
Roger Gadsby, et al.(2009)  review the efficacy and safety of sitagliptin and discuss its place in
therapy.Evidance from a Cochrane review and meta-analysis of 14 trials or study arms suggests
that sitagliptin lowers HbA1c by0.7% in sitagliptin versus placebo trials. Evidence from a pooled
safety database of 3415 people taking sitagliptin, and the Cochrane review show that the drug is
well tolerated, causes no hypoglycemia and is weight neutral. No specific signals of concern for
the safety of sitagliptin have so far arusen in the pooled database. Guidelines recommended its
use  in  triple  therapy with  metformin  and  sulphonylurea  in  dual  therapy  with  metformin  or
sulphonylurea  or  thiazolidinedione  in  certain  cercumstances.sitagliptin  from  this  initial  data
appears to be a safe, weight neutral and effective anti-diabetic agent.
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Akira Kanamori, et al. (2013) this study (as part of ASSET-K) aimed to investigate the efficacy
and safety of sitagliptin when it was administered for 1.5 years or longer, and to explore factors
associated with reduction of the therapeutic response. Out of 375 patients treated with sitagliptin
(50mg/day) at kanamori diabetes clinic between December 2009 and March2012, 133 could be
followed up for 72 weeks without interruption. After excluding 40 patients in whom the dosage
and/or types of concomitant medications were modified during that period, the remaining 93
were included in this analysis. Clinical indices, such as blood glucose, HbA1c, and body weight,
were  investigated  respectively.  Compliance  with  diet  and  exercise  therapy at  48 weeks  was
checked by a questionnaire. Sitagliptin showed good efficacy and safety when administered for
18  months  as  both  monotherapy  and  combination  therapy.  Inadequate  compliance  with
diet/exercise therapy and weight gain may be associated with an increase of HbA1c over time
during treatment with sitagliptin.
EleFerrannini,  et  al.  (2013) investigate  the  long-term safety  and  efficacy of  empagliflozin,
sitagliptin and metformin in patients with type 2 diabetes.in this  randomized, open label,78-
week  extension  study  of  two  12-week,blinded,dose-finding  studies  of
empagliflozin(monotherapy and add-on to metformin) with open-label comparators,272 patients
received  10mg  empagliflozin(166  as  add-on  to  metformin),  275  received  25  mg
empagliflozin(166  as  add-on  to  metformin),56  patients  received  metformin,  and  56  patients
received  sitagliptin  as  add-on  to  metformin.  Long-term  empagliflozin  treatment  provided
sustained glycemic and weight control and was well tolerated with a low risk of hypoglycemia in
patients with type 2 diabetes. 
GuntramSchernthaner, et al. (2013) evaluate the efficacy and safety of canagliflozin,a sodium
glucose  cotransporter  2  inhibitor,  compared with  sitagliptin  in  subjects  with  type  2  diabetes
inadequately controlled with metformin plus sulfonylurea. In this 52-week, randomized, double-
blind,  active-controlled,  phase  3  study,  subjects  using  stable  metformin  plus  sulfonylurea
(N=755) received canagliflozin 300 mg or sitagliptin 100mg daily. Primary end point was change
from baseline in A1C at  52 weeks.  Secondary end points included change in fasting plasma
glucose  (FPG)  and  systolic  blood  pressure  (BP),  and  percent  change  in  body  weight,
triglycerides, and HDL cholesterol, Safety was assessed based on adverse event (AE) reports.
Findings suggest that canagliflozin may be a new therapeutic tool providing better improvement
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in  glycemic  control  and  body  weight  reduction  than  sitagliptin,  but  with  increased  genital
infections in subjects with type 2 diabetes using metformin plus sulfonylurea. 
Ralph  A.Defronzo,  et  al.  (2009)  this  24-week  trial  assessed  the  efficacy  and  safety  of
saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control
with  metformin  alone.  This  was  a  randomized,  double-blind,  placebo-controlled  study  of
saxagliptin (2.5, 5, or 10mg once daily) or placebo plus a stable dose of metformin (1500-2500
mg)  in  743  patients  (A1c≥7.0  and  ≤  10.0%).Efficacy  analyses  were  performed  using  an
ANCOVA model  using last  observation carried forward methodology on primary (A1c)  and
secondary (fasting plasma glucose [FPG] and postprandial glucose [PPG] area under the curve
[AUC])  end  points.  Saxagliptin  once  daily  added  to  metformin  therapy  was  generally  well
tolerated and led to statistically significant improvements in glycemic indexes versus placebo
added to metformin in patients  with type 2 diabetes inadequately controlled with metformin
alone. 
Muthukrishnanjayaraman,  et  al.  (2013)  there reports of  acute pancreatitis  with  the use of
dipeptidyl peptidase-4 inhibitors (gliptins).This class of drugs is widely being prescribed for type
2 diabetes mellitus (DM) in our country. We evaluated the incidence of acute pancreatitis with
the use of gliptins during the period January 2012-june 2013.patients of type 2 DM on treatment
with any of the gliptins (sitagliptin, vildagliptin, or saxagliptin) for at least 1 month duration
were included. A total of 185 patients were included (205.3 patient years of follow-up).Five of
them had history of acute pancreatitis  (all mild) >6 months prior to inclusion with complete
resolution and no chronic pancreatitis. One patient (0.48 per 100 patient years) presented with
mild acute pancreatitis which resolved in 8 days. Asymptomatic elevation of serum amylase > 3x
upper  limit  of  normal  was  noted  in  five  patients  (2.4  per  100  patient  years),  without  any
sonological  evidence  of  pancreatitis.  This  resolved  on  withdrawal  of  gliptins.  None  of  the
patients with previous history of pancreatitis had a recurrence of pancreatitis. In a group at low
risk of acute pancreatitis, incidence of acute pancreatitis is low with the use of gliptins. 
Robert  Frederich,  et  al.(2012)  the  aim of  this  study was  to  assess  efficacy  and  safety  of
saxagliptin monotherapy for up to &76 weeks in patients with type 2 diabetes mellitus (T2DM)
and inadequate glycemic control, with main efficacy assessment at 24 weeks.365 treatment-naïve
patients with T2DM(HbA1c 7.0-10.0%) were treated with saxagliptin 2.5 mg q.A.M, saxagliptin
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2.5 mg q.A.M  with possible titration to saxagliptin 5 mg, saxagliptin 5mg q.A.M,saxagliptin 5
mg  q.P.M,or  placebo,  After  week  24,patients  in  all  groups  were  eligible  for  titration  to
saxagliptin  10 mg based  on HbA1c ≥7%, and all  unrescued  placebo patients  began  blinded
metformin  500  mg/day.  Rescue  with  open-label  metformin  was  available  for  patients  with
inadequate glycemic control. In treatment-naïve patients with T2DM, saxagliptin monotherapy
demonstrated statistically significant improvement in HbA1c compared with placebo at 24 weeks
and generally well tolerated for up to 76 weeks.   
Iftekar H,  et  al.  (2012)  type  2  diabetes  mellitus  (T2DM)  is  epidemic  in  most  developing
countries and is a leading cause of morbidity and mortality. Vildagliptin represent a new class of
oral  anti-diabetic  agent  that  enhance  the  action  of  incretin  hormone  through  inhibition  of
dipeptidylpeptidase-4.The  enhancement  of  incretin  hormone(GLP-1  &  GIP)  potentiates  the
insulin secretion in β-cells and suppress the glucagon release by α-cells in the pancreas. The
present article reviews the impact of DPP-4 inhibitor, Vildagliptin in monotherapy as well as
combination  with  a  special  emphasis  on the  Risk & Benefits  on different  organs  of  T2DM
patients.  Vildagliptin  is  a  potent  &  specific  DPP-4  inhibitor  that  has  demonstrated  weigh
neutrally, and improves β-cell as well as cardiovascular function in patient with DM type 2 in
multiple monotherapy & combination. However, hypoglycemic event reported with combination
of  metformin,  rosiglitazone  and  SU,  but  safe  with  pioglitazone,  while  in  combination  with
insulin the event was found to be reduced. Vildagliptin also shows feedback inhibition of GLP-1
secretion  which  reduces  risk  of  cardiovascular  and  hypoglycemia,  where  as  it  concern  to
increasing the risk of pancreatitis according to post marketing surveillance.  
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SITAGLIPTIN50, 51
DESCRIPTION:
Sitagliptin  is  a  new  oral  hypoglycemic  (anti-diabetic  drug)  of  the  new  dipeptidyl
peptidase4 (DPP-4) Inhibitor class of drugs.  Previously identified as MK-0431 and marketed as
the phosphate salt under the trade name Januvia.  It was developed, and is marketed, by Merck &
Co.  This enzyme-inhibiting drug is to be used either alone or in combination with Metformin or
a thiazolidinedione for control of type 2 diabetes mellitus.  The drug works to competitively
inhibit a protein / enzyme, dipeptidylpeptidase4 (DPP-4), that results in an increased amount of
active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release)
and increased release of insulin. 
STRUCTURE:
®-4-0xo-4-[3-  (trifluoromethyl)-5,  6diydro[1,2,4]  triazolo  [4,3-a]pyrazin-7  (8H)-yl]-1-(2,4,5-
trifluoropenyl) butan-2-amine.
Molecular weight =Average: 407.3136g/mol
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Molecular formula=C₁₆H₁₅F₅N₅O
MECHANISM OF ACTION:
Sitagliptin is a highly selective DPP-4 inhibitor, which is believed to exert its actions in
patients with type 2 diabetes by slowing the inactivation of incretin hormones, thereby increasing
the concentration and prolonging the action of these hormones.  Incretin hormones, including
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),  are
released by the intestine throughout the day, and levels are increased in response to a meal. 
These hormones are rapidly inactivated by the enzyme, DPP-4.  The incretins are part of
an endogenous system involved in the physiologic regulation of glucose homeostasis.  When
blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis
and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP.
GLP-1 also lowers glucagon secretion form pancreatic alpha cells, leading to reduced hepatic
glucose production.  By increasing and prolonging active incretin levels, sitagliptin increases
insulin release and decreases glucagon levels in the circulation in a glucose dependent manner.
These changes lead to a decrease in hemoglobin A1C (HbA1c) levels, as well as a lower fasting
and postprandial glucose concentration.  Sitagliptin demonstrates selectivity for DPP-4 and does
not  inhibit  DPP-8  or  DPP-9  activity  in  vitro  at  concentrations  approximating  those  from
therapeutic doses.  
INDICATION:
Adjunct to diet and exercise to improve glycemic control in adult patients with type 2
diabetes mellitus as monotherapy or as combination therapy.
PHARMACOKINETICS:
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Absorption 
Sitagliptin is rapidly absorbed, with a 100mg does reaching a Cmax of 950nM in 1 to 4h; AUC
was 8.52 mcM.  The bioavailability is approximately 87%
Distribution 
Vd is approximately 198 L.Plasma protein binding is 38% 
Metabolism 
Metabolism by CYP3A4 and, to a lesser degree, CYP2C8
Elimination 
Terminal  half-life  is  approximately  12.4h  and  renal  clearance  is  approximately
350ml/min.Approximately 13% excreted in the feces and 87% in the urine via active tubular
secretion (79% as unchanged drug). Sitagliptin is substrate for organic anion transport. 
PHARMACODYNAMIC: 
Sitagliptin  is  an  orally-active  member  of  the  new  dipeptidyl  peptidase-4  (DPP-4)
inhibitor class of drugs.  The benefit of this medicine is expected to be its lower side-effects of
hypoglycemia in the control of blood glucose values.  The drug works to diminish the effects of a
protein/enzyme (by the inhibition of this protein/enzyme) on the pancreas at the level of release
of  glucagon  (diminishes  its  release)  and  at  the  level  of  insulin  (increases  its  synthesis  and
release) until blood glucose levels are restored toward normal, in which case the protein/enzyme
inhibitor becomes less effective and the amounts of insulin released diminishes thus diminishing
the “overshoot” of hypoglycemia seen in other oral hypoglycemic agents.  
DOSE AND ADMINISTRATION:
Adult
 PO 100mg once daily
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Adults  moderate  renal  impairment  (crc130  to  less  than  50ml/min  or  approximate  serum
creatinine levels of more than 1.7 up to 3mg/dl in men and more than 1.5 up to 2.5mg/dl in
women). 
PO 50mg once daily
Severe renal  impairment (Crcl  less than 30ml/min or approximate serum creatinine levels of
more than 3mg/dl in men and more than 2.5mg/dl in women).
PO 25mg once daily
Administer without regard the timing of hemodialysis. 
CONTRAINDICATION:
History of serious hypersensitivity reaction to sitagliptin. 
DRUG INTERACTION:
Cyclosporine
Sitagliptin plasma concentration may be increased modestly (approximately 68%), wich is not
expected to be clinically important. 
Digoxin
Digoxin concentration may be increased slightly (approximately 18%), no dosage adjustment is
recommended. 
Insulin, sulfonylureas (eg: tolbutamide)
ADVERSE DRUG REACTION:
GI
Diarrhea (3%). abdominal pain (2%) nausea (1%); post marketing report pancreatitis. 
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Respiratory 
Nasopharyngitis, upper respiratory tract infection (5%)
Miscellaneous
Headache(1%), hypoglycemia.
PRECAUTION:
Periodically  monitor  blood  glucose  and  HbA1c.  Assess  renal  function  prior  to  initiation  of
therapy  and  periodically  thereafter.  Observe  patients  carefully  for  signs  and  symptoms  of
pancreatitis. 
STORAGE AND STABILITY:
Store at 59° to 86° F
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                                                       LINAGLIPTIN50, 51
DESCRIPTION:
Linagliptin (BI-1356, trade name Tradjenta and Trajenta) is a DPP-4 inhibitor developed
by Boehringer ingelheim for treatment of type II diabetes.  Linagliptin (once daily) was approved
by the  food  and  drug administration  (FDA) on  2011 and  is  being  marketed  by Boehringer
ingelheim and Lilly. 
STRUCTURE:
8-[(3R)-3-aminopiperidin-1yl]-7-(but-2yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2yl)  methyl]-
3, 7dihydro-1-H-purine-2, 6-dione 
Molecular weight =472.54g/mol
Molecular formula= C₂₅H₂₈N₈O₂
ULTRA COLLEGE OF PHARMACY , MADURAI PAGE 34
           	
MECHANISM OF ACTION:
Linagliptin is a competitive and reversible dipeptidyl peptidase (DPP)-4 enzyme inhibitor
that slows the breakdown of insulinotropic hormone glucagon-like peptide (GLP)-1 for better
glycemic control in diabetes patients.  GLP and glucose-dependent insulinotropic polypeptide
(GIP) are incretin hormones that increase the production and release of insulin from pancreatic
beta cells and decrease the release of glucagon from pancreatic alpha cells.  This results in an
overall  decrease  in  glucose  production  in  the  liver  and  increase  an  of  insulin  in  a  glucose
dependent manner.  
INDICATION:
Linagliptin is used for the management of type 2 diabetes mellitus.  
PHRAMACOKINETICS:
Absorption
Cmax, 5mg, healthy subjects=8.32nmol/L; Tmax, 5mg, healthy subjects =1.75 hours; AUC (0-24
hours), 5mgn, healthy subjects=119 nmol h/L; Bioavailability, healthy subjects=30%. When a
dose of 5mg once daily is given, steady state is achieved by the third dose.  Although a high fat
meal reduces Cmax and increase AUC, this interaction with food is not clinically significant.
Linagliptin may be administered with or without food.
Distribution
Vd=1110L, 70-80% protein bound.
Metabolism
Linagliptin is not extensively metabolized, 90% of does is excreted unchanged. The small
portion of drug that is metabolized, the main metabolite is CD1790 and is pharmacologically
inactive.  Glucuronidation forms some.
Elimination
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Linagliptin is eliminated via the faces/ enterohepatic system (80%) and urine (5%).  This
is unlike other DPP-4 inhibitors which are primarily eliminated by the renal system.  Terminal
half-life=131 hours.   Because of this long half-life,  inhibition of DPP-4 activity is  sustained
which indicates that once-daily dosing is appropriate.  Effective half-life for accumulation of
drug is 12 hours when multiple.  Renal clearance, steady state=mL/min.
PHARMACODYNAMICS:
Linagliptin is more potent inhibitor of DPP-4 than other drugs that belongs to the same
class with an IC50 of 1 nM. In comparison, sitagliptin, saxagliptin, and vildagliptin have an IC50
of 19, 50, and 62nM respectively.  A dose of 2.5 and 5mg reduces the activity of DPP-4 by
72.7% and 86.1% from respectively in healthy male subjects.  In diabetes patients, a dose of 5
and 10mg inhibits >90% of DPP-4.  Linagliptin is also selectively inhibits DPP-4 as indicated by
the lack of DPP-8 or DPP-9 inhibition at therapeutic exposures in vitro.
DOSE AND ADMINISTRATION:
Adult
PO 5mg once daily.
CONTRANDICATION:
Produce history of serious hypersensitivity reaction for linagliptin.
DRUG INTERACTION:
Carbamazepine: CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin.
Monitor concomitant therapy closely.
Etravirine: Linagliptin,  when used concomitantly with etravirine (a strong CYP3A4
Inducer,  may  experience  a  decrease  in  serum  concentration;  It  is
recommended  to  avoid  concurrent  therapy  if  possible,  and  to  monitor
Linagliptin therapy if concurrent cannot be avoided.
Hydrocortisone: CYP3A4 inducers  may decrease  levels  of  Linagliptin  and  diminish  the
hypoglycemic effect of anti-diabetic agents.
Prednisone: CYP3A4  inducers  may  decrease  level  of  Linagliptin  and  diminish  the
hypoglycemic effect of anti-diabetic agents.
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Rifampin: CYP3A4 and p-glycoprotein inducers may decreases levels of Linagliptin.
Ritonavir: CYP3A4 inhibitors may increase levels of linagliptin.
ADVERSE DRUG REACTION:
Nasopharyngitis, Rash, hypoglycemia,
PRECAUTION:
When used with  an insulin  secretagogue (e.g.  Sulfonylurea)  or  with insulin,  consider
lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. 
The use of Linagliptin with insulin was associated with a higher rate of hypoglycemia in
patients with severe renal impairment and a lower dose of insulin may be required. 
Safety and effectiveness have not been established in pediatric patients (less than 18 years
of age).
WARNINGS:
Linagliptin has been assigned to pregnancy category B by the FDA.
There are no data on the excretion of Linagliptin into human milk.  The manufacturer
recommends that caution be used when administering linagliptin to nursing women.
STORAGE
Store at room temperature away from moisture and heat. 
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AIM AND OBJECTIVE
AIM AND OBJECTIVE
AIM:
The aim of the present study was to compare the efficacy and safety of linagliptin with that of
sitagliptin among type 2 diabetic patients”.
OBJECTIVE:
 To assess the comparative efficacy of the DPP-4 inhibitors linagliptin/sitagliptin through,
Fasting plasma glucose (FPG), post prandial glucose (PPG) and glycated haemoglobin
(HbA1c) levels along with lipid profile and BMI measure in a period of 6 months.
 To evaluate and compare the safety of the linagliptin/sitagliptin drugs by following the
assessment of renal profile, hepatic profile (Liver Function Test).  
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The present dissertation work was planned to conduct a “comparative study on efficacy
and safety of linagliptin vs. sitagliptin drugs in the treatment of type 2 diabetes mellitus”.
And was planned to conduct in Annamalai diabetic research center at Karaikudi.
The plan of work includes: 
1. Submission of the protocol for getting the approval from ethical committee.
2. To get consent letter from patient.
3. To design a data collection form.
4. To collect the case histories of the patient with type2 diabetes.
5. To divide the patient into two groups randomly.
6. Fasting  blood  glucose  (FPG),  post  prandial  glucose  (PPG),  glycated  haemoglobin
(HbA1c), body mass index (BMI), Lipid profile, Renal profile, Hepatic profile values are
measure at baseline and end of the study.
7. To evaluate collected data.
8. Carrying out statistical analysis and recorded.
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STUDY DESIGN: 
This study is aProspective observational study.
STUDY SETTING:                                               
              The study was carried out on type 2 diabetic patients visiting the outpatient department
in Annamalai diabetic care and research center, Karaikudi.It is one of the reputed Hospital in
karaikudi.Majority of patients come from the surrounding rural areas. 
SOURCE OF DATA:
The required data was collected by using data collection form.
POPULATION SIZE:
A total  100 patients  were enrolled for the study.  The patients were randomly divided into 2
groups, In which 50 patients each were group A (linagliptin 5 mg) and group B (sitagliptin 100
mg).
STUDY CRITERIA:
Inclusion criteria:
• Glycosylated haemoglobin>7%
• Patients of age between 30-70 years.
• Type 2 diabetic patients.
      Exclusion criteria:
• Type 1 diabetic patient.
• Diabetic ketoacidosis
• Patient with renal and hepatic dysfunction.
• Pregnant lactating women.
STUDY PERIOD:
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Study was conducted for a period of 6 months.
(September 2013 to February 2014)
ETHICAL APPROVAL:
 The institutional human ethical committee of MGR university approved the study.
INFORMED CONSENT:
 A suitably prepared consent form was used for the purpose of the study.
METHODOLOGY
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STATISTICAL ANALYSIS:
Data analysis was done with help of computer using Instat package(version 0.36, 2003)
DATACOLLECTION:
 Those patients receive linagliptin, sitagliptin were introduced in group A and group B.
 The patients were given instruction to monitor their blood glucose level, HbA1c, lipid
profile,  renal  profile,  and  hepatic  profile  (Liver  Function  Test)  at  the  initial  visit  to
hospital.
 The patient  records  were maintained for the next six  month after  their  initial  visit  to
hospital.
 The patients were observed for weight, height and BMI measurement.
 The records of age, sex and other possible associated diseases were also maintained.
 The  patients  were  asked  for  the  determination  of  blood  glucose  level,HbA1c,  lipid
profile, renal profile, and hepatic profile (LFT) .regularly at the interval of 3 months up to
end of  the study .
PRIMARY PARAMETER                             SECONDARY PARAMETER        
1. Fasting glucose level:                                                                 Lipid profile
2. PPG:                                                                                              1.TC, TGL
3. HbA1c value:                                                                                2.LDL  
4. BMI value:                                                                                    3.HDL
RENAL SAFETY                                                HEPATIC SAFETY      
1. Serum creatinine:                                                                         1.Total bilirubin:     
2. Uric acid:                                                                                      2. ALT/ SGPT:
3. Urea:                                                                                             3. AST/ SGOT:
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The work entitled “comparison on efficacy and safety of Linagliptin Vs. sitagliptin among
type 2 diabetic patients”. Was carried out in Annamalai Diabetic research centre, Karaikudi.A
total of 100 patients were randomized to include in this study. There patients were distributed
into two groups such as Group A on Linagliptin. Group B on Sitagliptin.
            All patients baseline parameters were recorded before the treatment as initial values and
recorded at  each follow up. Also values  of  all  parameters  were recorded after  6 month and
compared the values.
           The information collected recording all the selected cases were recorded in a master chart.
Data analysis was done with the help of computer using Instat package (version 3.06, 2003).
Using this software means, standard deviations, ’p’ values were calculated. Paired t test was used
to test the significance of difference between quantitative variables and qualitative variables.A’p’
value less than 0.05 is taken to denote significant relationship.
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                                          PATIENT DEMOGRAPHY
                                                    Table 1: Age distribution                                                             
              AGE 
           GROUP  A            GROUP  B    TOTAL    NO    
OF        
 PATIENTS
  NO  OF 
PATIENTS
PERCENTAGE
          (%)
  NO  OF 
PATIENTS
PERCENTAGE
        (%)
40 to 50 YEARS
      23           46      23         46               46
51 to 60 YEARS
      27           54      27         54               54
TOTAL
      50      50             100
Out of 100 patients, 50 patients were Group A, from these 23 patients (46%) were age between
40-50 years, and 27 patients (54%) were age between 51-60 years.
Out of 100 patients, 50 patients were Group B, from these 23 patients (46%) were age between
40-50 years, and 27 patients (54%) were age between 51-60 years.  
                                                                 FIGURE: 1
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OBSERVATION AND RESULTS
                                                       Table 2: Sex distribution
             SEX
            GROUP A          GROUP  B    TOTAL   NO   
OF    
       PATIENTS
NO OF 
PATIENTS
PERCENTAGE
        (%)
NO OF 
PATIENTS
PERCENTAGE
         (%)
MALE
      26          52      26          52              52
FEMALE
      24          48      24          48              48
TOTAL
      50      50             100
A total of 100 patients were screened and randomized into two treatment groups. Out of 50 on
Group A, from these 26 patients (52%) were male and 24 patients (48%) were female. 
Out of 50 on Group B, from these 26 patients (52%) were male and 24 patients (48%) were
female.
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                                                                         FIGURE: 2
                                                               Table 3: Duration of DM
 DURATION  OF  DM
         (IN  YEARS)
           GROUP A           GROUP  B
NO OF 
PATIENTS
PERCENTAGE
         (%)
NO OF 
PATIENTS
PERCENTAGE
          (%)
0 TO 3 YEARS
     11        22       14          28
4 TO 7 YEARS
     34        68       33          66
ABOVE 7 YEARS
     5        10       3          6
 TOTAL
    50     50
Out Of 100 patients, 50 patients were Group A, from these 11 patients (22%) duration of DM
were between 0-3 years, 34 patients (68%) duration of DM were 4-7 years, and 5 patients (10%)
duration of DM were above 7 years.
Another 50 patients were Group B, from these 14 patients (28%) duration of DM were between
0-3 years, 33 patients (66%) duration of DM were 4-7 years, and 3 patients (6%) duration of DM
were above 7 years.
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OBSERVATION AND RESULTS
                                                                   FIGURE: 3
                                      EFFICACY MEASUREMENT
                                           Table 4: Fasting plasma glucose value
PATIENTS  VISIT  TO
HOSPITAL
FASTING PLASMA  GLUCOSE   VALUE  IN
MEAN ±SD (Mg/dl)
‘P’ VALUE
GROUP A GROUP  B
FIRST VISIT 132.1±19.32 130.8±19.95 0.6902Not significant
SECOND  VISIT 105.2±3.4 114.8±8.7 0.0001Significant
THIRD  VISIT 100.2±12.3 112.1±13.9 0.0001Significant
MEAN CHANGE IN
SECOND VISIT 26.9±15.9 16±11.2
0.0001
Significant
MEAN CHANGE IN THIRD
VISIT 31.9±7.02 18.7±6.05
0.0001
Significant
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The fasting plasma glucose values were had significance reduction in two groups. The reduction
of fasting plasma glucose, group A was greater than that in the group B.
Order of reduction =Group A > Group B
The P value of  fasting plasma glucose after  second and third  visit  were 0.0001,  which was
significant.P value of decreasing blood sugar after second and third visit were 0.0001, which was
also significant.
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OBSERVATION AND RESULTS
                                                                          FIGURE: 4
                                       Table 5: Post prandial plasma glucose value
PATIENT  VISIT  TO   
         HOSPITAL
  POST PRANDIAL  PLASMA   GLUCOSE  
VALUE   AT MEAN ±SD(Mg/dl)
           ‘P’ VALUE
           GROUP A            GROUP  B
FIRST VISIT 221.6±18.9 217.7±26.4 0.3847Not significant
SECOND VISIT 138.6±16.3 168.1±14.6
0.0001
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significant
THIRD VISIT 136.6±16.1 149.5±11.7 0.0001Significant
MEAN CHANGE IN
SECOND VISIT 83±2.6 49.6±11.8 0.0001
Significant
MEAN CHANGE IN THIRD
VISIT 85±2.8 68.2±14.7 0.0001
Significant
The post prandial plasma glucose values were had significance reduction in two groups. The
reduction of fasting plasma glucose, group A was greater than that of group B.
Order of reduction =Group A > Group B
The P value of post prandial plasma glucose after second and third visit were 0.0001, which was
significant.P value of decreasing post prandial after second and third visit were 0.0001, which
was also significant.
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                                                                 FIGURE: 5
                                                          Table 6: HbA1c value
PATIENTS VISIT TO
HOSPITAL
HbA1c VALUE IN MEAN ±SD (%)
‘P’ VALUEGROUP A GROUP  B
FIRST  VISIT 7.7±0.4 0.7906
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7.7±0.3 Not significant
SECOND VISIT 6.6±0.5 7.3±0.48 0.0001
significant
THIRD VISIT 6.5±0.4 6.9±0.5               0.0001Significant
MEAN CHANGE IN
SECOND VISIT 1.1±0.2 0.4±0.08
0.0001
significant
MEAN CHANGE IN THIRD
VISIT 1.2±0.1 0.8±0.1
             0.0001
significant
The HbA1c levels were found to be reduced significance in patients with two groups. 
The group Ashowed greater reduction in HbA1c after third visit. 
Order of reduction in HbA1c = Group A > Group B
The P value of HbA1c after third visit was 0.0001, which was significant. 
                                                                     FIGURE: 6
                                                Table 7: Body mass index value
BMI  (Kg/m2) ‘P’ VALUE
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PATIENTS VISIT TO
HOSPITAL GROUP A GROUP  B
              FIRST  VISIT
            25.93±1.15             25.83±1.15 0.6647Not significant
THIRD VISIT 25.92±1.13 25.85±1.0               0.7436Not significant
BMI CHANGE IN THIRD
VISIT 0.01±0.02 0.02±0.15
0.6413
Not significant
The BMI levels were found to be not significance in patients with group A and group B. The
P value of BMI after third visit was 0.7436, which was not statistically significant. The P value
of BMI change after third visit was 0.6413, which was also not significant.
                                                                      FIGURE: 7 
                                         SECONDARY PARAMETER
                                                            LIPID PROFILE
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                                                   Table 8: Total cholesterol value
PATIENT  VISIT TO 
HOSPITAL
TOTAL CHOLESTEROL VALUE IN  
              MEAN±SD   (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
TC TC
FIRST  VISIT 168.6±12.8 169.7±11.8 0.6683
Not significant
SECOND VISIT 167.22±23.14 168.84±17.29 0.6955
Not Significant
THIRD VISIT 166.12±22.71 168.38±19.39 0.5648
Not Significant
MEAN CHANGE IN
SECOND VISIT 1.38±10.34 0.86±5.49
0.7543
Not significant
MEAN CHANGE IN
THIRD VISIT 2.48±9.91 1.32±7.59
0.5128
Not significant
The mean total cholesterol level were had not significance reduction in two groups. The mean
change of total cholesterol, group A was high than that of group B.
Order of reduction= Group A > Group B
The P values of total cholesterol after second and third visit were 0.6955, 0.5648 which was not
significant.P  values  of  total  cholesterol  mean  change  in  after  second  and  third  visit  were
0.7543,0.5128 which was also not significant.
FIGURE: 8
                                                         Table 9: Triglycerides value
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PATIENT  VISIT TO 
HOSPITAL
TRIGLYCERIDES VALUE IN       
               MEAN±SD  (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
TGL TGL
FIRST  VISIT 137±14.2 139.9±12.9 0.2267
Not significant
SECOND VISIT 134.72±13.57 138.84±13.19 0.0889
Not significant
              THIRD VISIT 131.2±18.82 136.64±14.95 0.0766
Not significant
MEAN CHANGE IN
SECOND VISIT 2.28±0.63 1.06±0.29
0.0001
significant
MEAN CHANGE IN
THIRD VISIT 5.8±4.62          3.26±2.05
0.0007
significant
The mean triglycerides levels  were had not significance reduction in two groups.  The mean
change of triglycerides, group A was high than that of group B.
Order of reduction= Group A > Group B
The P values of triglycerides after second and third visit were 0.0889, 0.0766 which was a not
significant.P value of  triglycerides  mean change in  after  second and third visit  were 0.0001,
0.0007 which was significant.
FIGURE: 9 
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                                                      Table 10: Low density lipid value
PATIENT  VISIT TO 
HOSPITAL
LOW DENSITY LIPID VALUE IN          
             MEAN±SD (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
LDL LDL
FIRST  VISIT 96±12.7 99.3±15.9 0.1747
Not significant
SECOND VISIT 94.3±17.0 97.96±17.44 0.3093
Not Significant
THIRD VISIT
       91.74±20.27 96.18±18.52 0.2482
Not Significant
MEAN CHANGE IN
SECOND VISIT 1.7±4.3 1.34±1.54
0.5793
Not Significant
MEAN CHANGE IN
THIRD VISIT 4.26±7.57 3.12±2.62
0.3183
Not significant
The mean low density lipid levels were had not significance reduction in two groups. The mean
change of low density lipid level, group A was high than that of group B.
Order of reduction= Group A > Group B
The P values of low density lipid after secondand third visit were 0.3093, 0.2482, which was not
significant.P values  of  low  density  lipid  mean  change  in  after  second  and  third  visit  were
0.5793,0.3183 which was also not significant.
FIGURE: 10
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                                                        Table 11: High density lipid value
PATIENT  VISIT TO 
HOSPITAL
HIGH DENSITY LIPID VALUE IN       
               MEAN±SD (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
HDL HDL
FIRST  VISIT 37.3±4.5 35.7±3.7     0.0742
Not significant
SECOND VISIT 40.2±4.3 36.9±5.1 0.0003
Significant
THIRD VISIT 43.4±3.9 38.4±8.7 0.0001
Significant
MEAN CHANGE IN  
SECOND VISIT 2.9±0.2 1.2±1.4
0.0001
Significant
MEAN CHANGE IN     
THIRD VISIT 6.1±0.6 2.7±5.0
0.0001
Significant
The mean high density lipid levels were had significant increase in two groups. The mean change
of high density lipid, group A was greater than that of group B.
Order of increase = Group A > Group B
The P values of high density lipid after visit  0.0003 and third visit  were 0.0001, which was
significant.P values  of  high  density  lipid  mean  change  in  after  second  and  third  visit  were
0.0001, which was also significant.
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FIGURE: 11
                                             SAFETY MEASUREMENT
                                                              RENAL PROFILE                   
                                                     Table 12: Serum creatinine value
PATIENT  VISIT TO 
HOSPITAL
SERUM CREATININE VALUE IN   
               MEAN±SD  (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
SR  CR SR CR
FIRST  VISIT 0.97±0.05 0.98±0.04  0.8372
Not significant
SECOND VISIT 0.96±0.09 0.97±0.06 0.5453
Not significant
THIRD VISIT 0.98±0.09 1.00±0.07 0.1824
Not significant
MEAN CHANGE IN  
SECOND VISIT 0.01±0.04 0.01±0.02
0.9999
Not significant
MEAN CHANGE IN     
THIRD VISIT 0.01±0.04 0.02±0.03
0.1605
Not significant
The patients mean values of serum creatinine showed changes slightly but not significance in
group A and group B.The P value of serum creatinine after second visit 0.5453 and third visit
was 0.1824, which was not statistically significant. The P value of serum creatinine mean change
second and third visit respectively 0.9999, 0.1605, which was also not significant.
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                                                                     FIGURE: 12
                                                            Table 13: Blood urea value
PATIENT  VISIT TO 
HOSPITAL
         BLOOD UREA VALUE IN 
             MEAN±SD  (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
B U B U
FIRST  VISIT 27.66±3.28 27.78±3.20 0.8457
Not significant
SECOND VISIT 27.56±3.58 27.76±3.55 0.7541
Not significant
THIRD VISIT 27.62±3.1 27.84±3.5 0.7452
Not significant
MEAN CHANGE IN
SECOND VISIT 0.1±0.3 0.02±0.35
0.2227
Not significant
MEAN CHANGE IN
THIRD VISIT 0.04±0.1 0.06±0.3
0.6557
Not significant
The patients mean values of blood urea showed changes slightly but not significance in group A
and group B.The P value of blood urea after second visit 0.7541 and third visit  was 0.7452,
which was not statistically significant. The P values of blood urea mean changes in second and
third visit respectively 0.2227, 0.6557, which was also not significant.
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                                                                    FIGURE: 13
                                                Table 14: serum uric acid value
PATIENT  VISIT TO 
HOSPITAL
  SERUM URIC ACID VALUE IN      
          MEAN±SD  (Mg/dl)      ‘P’  VALUE
GROUP A GROUP B 
SUA SUA
FIRST  VISIT 4.36±0.7  4.47±0.62 0.3669
Not significant
SECOND VISIT 4.40±0.6 4.41±0.66 0.9293
Not significant
THIRD VISIT 4.37±0.6 4.49±0.63 0.3033
Not significant
MEAN CHANGE IN  
SECOND VISIT 0.04±0.1                     0.06±0.04                    
0.1922
Not significant
MEAN CHANGE IN     
THIRD VISIT 0.01±0.1  0.02±0.01                  
0.4834
Not significant
The patients mean values of serum uric acid showed changes slightly but not significance in
group A and group B.The P value of serum uric acid after second visit 0.9293 and third visit was
0.3033, which was not statistically significant. The P values of serum uric acid mean change in
second and third visit respectively 0.1922, 0.0.4834, which was also not significant.
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                                                                     FIGURE: 14
                                HEPATIC PROFILE (LIVER FUNCTION TEST)
                                                       Table 15: Total bilirubin value
PATIENT  VISIT TO 
HOSPITAL
TOTAL BILIRUBIN VALUE IN 
           MEAN±SD (Mmol/L)      ‘P’  VALUE
GROUP A GROUP B 
        T B         TB
FIRST  VISIT 0.95±0.05 0.95±0.06       0.9999         
 Not significant
SECOND VISIT 0.94±0.06 0.96±0.07       0.0673
Not significant
THIRD VISIT 0.96±0.06 0.94±0.07      0.3414
Not significant
MEAN CHANGE IN
SECOND VISIT 0.01±0.01 0.01±0.01
     0.9999
Not significant
MEAN CHANGE IN
THIRD VISIT 0.01±0.01 0.01±0.01
     0.9999
Not significant
The patients mean values of total bilirubin showed changes slightly but not significance in group
A and group B.The P value of total bilirubin after second visit 0.0673 and third visit was 0.3414,
which was not statistically significant. The P values of total bilirubin mean changes in second
and third visit respectively 0.9999, 0.9999, which was also not significant.
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FIGURE: 15
                                                          Table 16:  SGOT/ALT values
PATIENT  VISIT TO 
HOSPITAL
                SGOT/ALT VALUE IN  
                      MEAN±SD (U/L)      ‘P’  VALUE
GROUP A GROUP B 
SGOT/ALT SGOT/ALT
FIRST  VISIT 28.82±4.2 29.02±4.74    0.8228
Not significant
SECOND VISIT 28.42±4.27 29.54±3.92     0.1846
Not significant
THIRD VISIT 28.76±5 29.1±4.9     0.6958
Not significant
MEAN CHANGE IN  
SECOND VISIT 0.4±0.07 0.52±0.82
     0.3807
Not significant
MEAN CHANGE IN     
THIRD VISIT 0.04±0.08 0.08±0.16
      0.1171
Not significant
The patients mean values of SGOT/ALT showed changes slightly but not significance in group A
and group B.The P value of SGOT/ALT after second visit 0.1846 and third visit was 0.6958,
which was not statistically significant. The P values of serum creatinine mean changes in second
and third visit respectively 0.3807, 0.1171, which was also not significant.
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                                                                      FIGURE: 16
                                                           Table 17: SGPT/AST values
PATIENT  VISIT TO 
HOSPITAL
                 SGPT/AST VALUE IN 
                      MEAN±SD (U/L)      ‘P’  VALUE
GROUP A GROUP B 
SGPT/AST SGPT/AST
FIRST  VISIT 29.1±4.2 29.6±3.9 0.4541
Not significant
SECOND VISIT 28.9±6.1 30.0±4.5 0.3180
Not significant
THIRD VISIT 29.2±5.1 29.7±3.8 0.6313
Not significant
MEAN CHANGE IN
SECOND VISIT 0.2±1.9 0.4±0.6
0.4795
Not significant
MEAN CHANGE IN
THIRD VISIT 0.1±0.9 0.1±0.1
0.9999
Not significant
The patients mean values of SGPT/AST showed changes slightly but not significance in group A
and group B.The P value of SGPT/AST after second visit 0.3180 and third visit was 0.6313,
which was not statistically significant. The P values of SGPT/AST mean changes in second and
third visit respectively 0.4795, 0.9999, which was also not significant.
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FIGURE: 17
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DISCUSSION
DISCUSSION
The results of this prospective observational study suggest that in patient with type 2
diabetes mellitus. Our study is the first to our knowledge, to investigate the efficacy and safety of
linagliptin vs. sitagliptin among type 2 diabetes mellitus.
 A total of 100 patients, 50 patients were Group A, from these 46% were age between 40-
50 years, and 54% were age between 51-60 years, in which 52% were male and 48%
were female. Remaining 50 patients were Group B, from these 46% were age between
40-50 years, and 54% were age between 51-60 years, in which 52% were male and 48%
were female.
 Out Of 100 patients, 50 patients were Group A, from these 22% patients duration of DM
were between 0-3 years,68% patients duration of DM were 4-7 years, and10% patients
duration of DM were above 7 years. Another 50 patients were Group B, from these 28%
patients duration of DM were between 0-3 years,66% patients duration of DM were 4-7
years, and 6% patients duration of DM were above 7 years.
 In this post hoc analysis of patients with T2DM showed significant and clinically relevant
reductions in fasting blood sugar, post prandial blood sugar, HbA1c level in group A and
group B, in which group A had greater reduction than group B.
  The BMI values of group A and group B had slight changes but P value of the both group
A and B were statistically not significant. That indicated weight should not be changed.
 The mean values of lipid profile were total cholesterol, LDL had reduced from baseline at
second and third visit on both group A and group B, but which was not significant on
mean and mean changes.  Even though numerically group A have high reduction than
group B. The mean values of triglycerides shown not significance at second and third
visit on both group A&B, but mean changes of second and third visit were statistically
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significant. The mean and mean change values of HDL were significantly increased from
baseline at second and third visit on both group A and group B, in which group A greater
than group B.
 The mean values of renal profile group A and group B were serum creatinine, blood urea,
serum uric acid had tiny changes but P values of the both groups were statistically not
significant. 
 The mean  values  of  hepatic  profile(LFT)  group  A and  group  B were  total  bilirubin,
SGOT/ALT,  SGPT/AST  had  tiny  changes  but  P  values  of  the  both  groups  were
statistically not significant. 
             Preventing or delaying the development of type 2 diabetes is major goals of treatment.
Our finding indicates that this goal can be achieved if high risk of patients are identified early in
the  course  of  disease  and  are  in  the  given  appropriate  therapy.  However,  renal  and  hepatic
impairment can be a limiting factor in the selection of antihyperglycemic therapies. Some of the
oral  hypoglycemic  drugs  have contraindication or  recommended dose adjustments  related to
renal  impairment.  Dose  adjustment  is  also  recommended  for  all  DPP-4  inhibitors  except
linagliptin when used in patients with moderate to severe renal impairment. Linagliptin, due to
its predominantly non-renal route of elimination, requires no dose adjustment.
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CONCLUSION
The results from the comparative study to evaluate the efficacy and safety of linagliptin
and sitagliptin drugs.      
 The present study shows that two drugs such as linagliptin and sitagliptin reduced the
fasting  plasma  glucose,  post  prandial  plasma  glucose  and  glycosylated  haemoglobin
level. But the linagliptin provided superior control of glycemic as compare to sitagliptin.
 There were no significant changes in BMI on both drugs.So linagliptin and sitagliptin had
good body weight control.
 There were favorable changes in lipid profiles in that linagliptin more favorable than
sitagliptin.
 Our study shows that insignificance of renal (Sr.Cr, BU, SUA) and hepatic (TB, ALT,
AST) profile. So both drugs were considered to be more safe.
It can be concluded with the results of the present study linagliptin possesses greater efficacy
with  increased  glycemic control  and  good safety compared  to  sitagliptin  in  Type  2 diabetic
patients.
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